Donoghue Forlines LLC Makes New $2.24 Million Investment in IQVIA Holdings Inc. $IQV

Donoghue Forlines LLC acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the third quarter, Holdings Channel reports. The institutional investor acquired 11,810 shares of the medical research company’s stock, valued at approximately $2,243,000.

Several other large investors have also added to or reduced their stakes in IQV. Fiduciary Family Office LLC increased its stake in IQVIA by 78.3% in the 3rd quarter. Fiduciary Family Office LLC now owns 6,153 shares of the medical research company’s stock valued at $1,169,000 after buying an additional 2,702 shares during the last quarter. Resonant Capital Advisors LLC bought a new position in shares of IQVIA in the 3rd quarter valued at about $210,000. Sequoia Financial Advisors LLC increased its position in shares of IQVIA by 9.3% in the third quarter. Sequoia Financial Advisors LLC now owns 6,401 shares of the medical research company’s stock valued at $1,216,000 after acquiring an additional 546 shares during the last quarter. OVERSEA CHINESE BANKING Corp Ltd bought a new stake in IQVIA during the third quarter worth about $1,917,000. Finally, Versant Capital Management Inc boosted its position in IQVIA by 6.3% during the third quarter. Versant Capital Management Inc now owns 899 shares of the medical research company’s stock valued at $171,000 after purchasing an additional 53 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insiders Place Their Bets

In related news, insider Eric Sherbet sold 4,000 shares of the business’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the sale, the insider directly owned 27,108 shares in the company, valued at $5,955,627.60. The trade was a 12.86% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 1.60% of the company’s stock.

Wall Street Analysts Forecast Growth

IQV has been the topic of a number of analyst reports. TD Cowen cut IQVIA from a “buy” rating to a “hold” rating and upped their price objective for the stock from $206.00 to $215.00 in a research note on Monday, November 3rd. Hsbc Global Res upgraded shares of IQVIA from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 9th. Morgan Stanley increased their price target on shares of IQVIA from $250.00 to $265.00 and gave the company an “overweight” rating in a research note on Monday, December 1st. HSBC upgraded shares of IQVIA from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $195.00 to $235.00 in a research note on Thursday, October 9th. Finally, Stifel Nicolaus raised their target price on shares of IQVIA from $234.00 to $254.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $249.19.

IQVIA Stock Performance

NYSE IQV opened at $238.03 on Friday. The stock has a market cap of $40.54 billion, a PE ratio of 32.65, a P/E/G ratio of 2.42 and a beta of 1.36. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70. The firm has a 50-day moving average of $227.30 and a 200-day moving average of $203.34. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $247.04.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. The business had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. IQVIA’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.